Because We're Worth It

Aug 14, 2008

Genentech finally came through with its long-expected rejection of Roche's acquisition bid, saying that the asking price "substantially undervalues the company," according to this story in the New York Times. Analysts predict that the companies will continue to negotiate, and that Roche will raise the offer from its original $43.7 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Asked to Give DNA Back

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

CCR5 Gene Mortality Paper Retracted

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

Catch It Before Being Hospitalized

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

PNAS Studies Look at Lung Cancer Models, Height in Ancient Europeans, More

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.

Menu